| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Accumulation and distribution of doxorubicin in tumour spheroids: the influence of acidity and expression of P-glycoprotein
|
Mellor, Howard R.
|
|
2011
|
68 |
5 |
p. 1179-1190
|
artikel
|
| 2 |
Aflibercept-mediated early angiogenic changes in aggressive B-cell lymphoma
|
Romero, Martha
|
|
2011
|
68 |
5 |
p. 1135-1143
|
artikel
|
| 3 |
Amrubicin for the treatment of neuroendocrine carcinoma of the gastrointestinal tract: a retrospective analysis of five cases
|
Asayama, Masako
|
|
2011
|
68 |
5 |
p. 1325-1330
|
artikel
|
| 4 |
A multicenter, randomized, open-label study to assess the steady-state pharmacokinetics of bevacizumab given with either XELOX or FOLFOX-4 in patients with metastatic colorectal cancer
|
Zhi, Jianguo
|
|
2011
|
68 |
5 |
p. 1199-1206
|
artikel
|
| 5 |
A novel method for quantification of gemcitabine and its metabolites 2′,2′-difluorodeoxyuridine and gemcitabine triphosphate in tumour tissue by LC–MS/MS: comparison with 19F NMR spectroscopy
|
Bapiro, Tashinga E.
|
|
2011
|
68 |
5 |
p. 1243-1253
|
artikel
|
| 6 |
A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapy
|
Pignata, S.
|
|
2011
|
68 |
5 |
p. 1347-1353
|
artikel
|
| 7 |
A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound in patients with refractory solid tumors
|
Simon, George R.
|
|
2011
|
68 |
5 |
p. 1233-1241
|
artikel
|
| 8 |
A phase 2 study of weekly albumin-bound paclitaxel (Abraxane®) given as a two-hour infusion
|
Paik, Paul K.
|
|
2011
|
68 |
5 |
p. 1331-1337
|
artikel
|
| 9 |
Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patients
|
De Stefano, Alfonso
|
|
2011
|
68 |
5 |
p. 1207-1213
|
artikel
|
| 10 |
Drug combinations with quercetin: doxorubicin plus quercetin in human breast cancer cells
|
Staedler, Davide
|
|
2011
|
68 |
5 |
p. 1161-1172
|
artikel
|
| 11 |
Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight
|
Min, Ji Hye
|
|
2011
|
68 |
5 |
p. 1099-1109
|
artikel
|
| 12 |
Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer
|
Carol, Hernan
|
|
2011
|
68 |
5 |
p. 1291-1304
|
artikel
|
| 13 |
First-line treatment of pancreatic cancer patients with the combination of 5-fluorouracil/folinic acid plus gemcitabine: a multicenter phase II trial by the CONKO-study group
|
Pelzer, Uwe
|
|
2011
|
68 |
5 |
p. 1173-1178
|
artikel
|
| 14 |
Furanodienone induces cell cycle arrest and apoptosis by suppressing EGFR/HER2 signaling in HER2-overexpressing human breast cancer cells
|
Li, Ying-Wei
|
|
2011
|
68 |
5 |
p. 1315-1323
|
artikel
|
| 15 |
Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study
|
Flaherty, Keith T.
|
|
2011
|
68 |
5 |
p. 1111-1118
|
artikel
|
| 16 |
Methotrexate toxicity and efficacy during the consolidation phase in paediatric acute lymphoblastic leukaemia and MTHFR polymorphisms as pharmacogenetic determinants
|
D’Angelo, Velia
|
|
2011
|
68 |
5 |
p. 1339-1346
|
artikel
|
| 17 |
MTHFR 677TT genotype and toxicity of methotrexate: controversial results
|
Lopez–Lopez, Elixabet
|
|
2011
|
68 |
5 |
p. 1369-1370
|
artikel
|
| 18 |
Pharmacokinetics of trabectedin on hemodialysis: an application for the management of cancer patients with end-stage renal disease
|
Thariat, Juliette
|
|
2011
|
68 |
5 |
p. 1363-1367
|
artikel
|
| 19 |
Pharmacologic and phenotypic study of docetaxel in patients with ovarian or primary peritoneal cancer
|
Zamboni, William C.
|
|
2011
|
68 |
5 |
p. 1255-1262
|
artikel
|
| 20 |
Phase II study of FOLFOX4 with “wait and go” strategy as first-line treatment for metastatic colorectal cancer
|
Kochi, Mitsugu
|
|
2011
|
68 |
5 |
p. 1215-1222
|
artikel
|
| 21 |
Phase I trial of metronomic oral vinorelbine in patients with advanced cancer
|
Rajdev, Lakshmi
|
|
2011
|
68 |
5 |
p. 1119-1124
|
artikel
|
| 22 |
Population pharmacokinetics and pharmacogenetics of vincristine in paediatric patients treated for solid tumour diseases
|
Guilhaumou, Romain
|
|
2010
|
68 |
5 |
p. 1191-1198
|
artikel
|
| 23 |
Preclinical evaluation of the antitumor activity of bortezomib in combination with vitamin C or with epigallocatechin gallate, a component of green tea
|
Bannerman, Bret
|
|
2011
|
68 |
5 |
p. 1145-1154
|
artikel
|
| 24 |
Pre-treatment lymphopenia as a prognostic biomarker in colorectal cancer patients receiving chemotherapy
|
Cézé, N.
|
|
2011
|
68 |
5 |
p. 1305-1313
|
artikel
|
| 25 |
Reply
|
D’Angelo, Velia
|
|
2011
|
68 |
5 |
p. 1371
|
artikel
|
| 26 |
Role of 12-lipoxygenase in regulation of ovarian cancer cell proliferation and survival
|
Guo, Austin M.
|
|
2011
|
68 |
5 |
p. 1273-1283
|
artikel
|
| 27 |
Severe fluoropyrimidine-related toxicity: clinical implications of DPYD analysis and UH2/U ratio evaluation
|
Giorgio, E.
|
|
2011
|
68 |
5 |
p. 1355-1361
|
artikel
|
| 28 |
Single nucleotide polymorphisms of CYP19A1 predict clinical outcomes and adverse events associated with letrozole in patients with metastatic breast cancer
|
Park, In Hae
|
|
2011
|
68 |
5 |
p. 1263-1271
|
artikel
|
| 29 |
Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function
|
Kim, Jeong Eun
|
|
2011
|
68 |
5 |
p. 1285-1290
|
artikel
|
| 30 |
Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function
|
Kim, Jeong Eun
|
|
|
68 |
5 |
p. 1285-1290
|
artikel
|
| 31 |
The iron chelator Dp44mT inhibits the proliferation of cancer cells but fails to protect from doxorubicin-induced cardiotoxicity in spontaneously hypertensive rats
|
Rao, V. Ashutosh
|
|
2011
|
68 |
5 |
p. 1125-1134
|
artikel
|
| 32 |
Thiopurine methyltransferase polymorphisms and mercaptopurine tolerance in Turkish children with acute lymphoblastic leukemia
|
Albayrak, Meryem
|
|
2011
|
68 |
5 |
p. 1155-1159
|
artikel
|
| 33 |
Trabectedin has a low cardiac risk profile: a comprehensive cardiac safety analysis
|
Lebedinsky, Claudia
|
|
2011
|
68 |
5 |
p. 1223-1231
|
artikel
|
Tijdschrift beschrijving